These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31546149)

  • 1. Targeted Delivery of C/EBPα-saRNA by RNA Aptamers Shows Anti-tumor Effects in a Mouse Model of Advanced PDAC.
    Yoon S; Huang KW; Andrikakou P; Vasconcelos D; Swiderski P; Reebye V; Sodergren M; Habib N; Rossi JJ
    Mol Ther Nucleic Acids; 2019 Dec; 18():142-154. PubMed ID: 31546149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo.
    Yoon S; Huang KW; Reebye V; Mintz P; Tien YW; Lai HS; Sætrom P; Reccia I; Swiderski P; Armstrong B; Jozwiak A; Spalding D; Jiao L; Habib N; Rossi JJ
    Mol Ther; 2016 Jun; 24(6):1106-1116. PubMed ID: 26983359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted delivery of CEBPA-saRNA for the treatment of pancreatic ductal adenocarcinoma by transferrin receptor aptamer decorated tetrahedral framework nucleic acid.
    Wang L; Yao Q; Guo X; Wang B; Si J; Wang X; Jing S; Yan M; Shi Y; Song G; Shen X; Guan J; Zhao Y; Zhu C
    J Nanobiotechnology; 2024 Jul; 22(1):392. PubMed ID: 38965606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Pancreatic Cancer by Aptamer Conjugated C/EBPα-saRNA.
    Yoon S; Rossi JJ
    Adv Exp Med Biol; 2017; 983():173-188. PubMed ID: 28639199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models.
    Mahajan UM; Li Q; Alnatsha A; Maas J; Orth M; Maier SH; Peterhansl J; Regel I; Sendler M; Wagh PR; Mishra N; Xue Y; Allawadhi P; Beyer G; Kühn JP; Marshall T; Appel B; Lämmerhirt F; Belka C; Müller S; Weiss FU; Lauber K; Lerch MM; Mayerle J
    Gastroenterology; 2021 Sep; 161(3):996-1010.e1. PubMed ID: 34097885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms involved in the activation of C/EBPα by small activating RNA in hepatocellular carcinoma.
    Zhao X; Reebye V; Hitchen P; Fan J; Jiang H; Sætrom P; Rossi J; Habib NA; Huang KW
    Oncogene; 2019 May; 38(18):3446-3457. PubMed ID: 30643190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo.
    Reebye V; Sætrom P; Mintz PJ; Huang KW; Swiderski P; Peng L; Liu C; Liu X; Lindkaer-Jensen S; Zacharoulis D; Kostomitsopoulos N; Kasahara N; Nicholls JP; Jiao LR; Pai M; Spalding DR; Mizandari M; Chikovani T; Emara MM; Haoudi A; Tomalia DA; Rossi JJ; Habib NA
    Hepatology; 2014 Jan; 59(1):216-27. PubMed ID: 23929703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C/EBPα Short-Activating RNA Suppresses Metastasis of Hepatocellular Carcinoma through Inhibiting EGFR/β-Catenin Signaling Mediated EMT.
    Huan H; Wen X; Chen X; Wu L; Liu W; Habib NA; Bie P; Xia F
    PLoS One; 2016; 11(4):e0153117. PubMed ID: 27050434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Liver Cancer by C/EBPA saRNA.
    Zhao X; Voutila J; Ghobrial S; Habib NA; Reebye V
    Adv Exp Med Biol; 2017; 983():189-194. PubMed ID: 28639200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aptamer-SH2 superbinder-based targeted therapy for pancreatic ductal adenocarcinoma.
    Liu AD; Zhou J; Bi XY; Hou GQ; Li SS; Chen Q; Xu H; Cao X
    Clin Transl Med; 2021 Mar; 11(3):e337. PubMed ID: 33783993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPα.
    Yamamoto K; Tateishi K; Kudo Y; Sato T; Yamamoto S; Miyabayashi K; Matsusaka K; Asaoka Y; Ijichi H; Hirata Y; Otsuka M; Nakai Y; Isayama H; Ikenoue T; Kurokawa M; Fukayama M; Kokudo N; Omata M; Koike K
    Carcinogenesis; 2014 Nov; 35(11):2404-14. PubMed ID: 24947179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrigendum to "Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo".
    Mol Ther; 2016 Dec; 24(12):2131-2132. PubMed ID: 27966559
    [No Abstract]   [Full Text] [Related]  

  • 13. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-κB-related signaling.
    Kuo SH; Yang SH; Wei MF; Lee HW; Tien YW; Cheng AL; Yeh KH
    Cancer Cell Int; 2021 Aug; 21(1):436. PubMed ID: 34412631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCAAT/enhancer binding protein alpha interacts with ZTA and mediates ZTA-induced p21(CIP-1) accumulation and G(1) cell cycle arrest during the Epstein-Barr virus lytic cycle.
    Wu FY; Chen H; Wang SE; ApRhys CM; Liao G; Fujimuro M; Farrell CJ; Huang J; Hayward SD; Hayward GS
    J Virol; 2003 Jan; 77(2):1481-500. PubMed ID: 12502863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma.
    Clawson GA; Abraham T; Pan W; Tang X; Linton SS; McGovern CO; Loc WS; Smith JP; Butler PJ; Kester M; Adair JH; Matters GL
    Nucleic Acid Ther; 2017 Feb; 27(1):23-35. PubMed ID: 27754762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer.
    Hashimoto A; Sarker D; Reebye V; Jarvis S; Sodergren MH; Kossenkov A; Sanseviero E; Raulf N; Vasara J; Andrikakou P; Meyer T; Huang KW; Plummer R; Chee CE; Spalding D; Pai M; Khan S; Pinato DJ; Sharma R; Basu B; Palmer D; Ma YT; Evans J; Habib R; Martirosyan A; Elasri N; Reynaud A; Rossi JJ; Cobbold M; Habib NA; Gabrilovich DI
    Clin Cancer Res; 2021 Nov; 27(21):5961-5978. PubMed ID: 34407972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice.
    Zhou J; Li H; Xia X; Herrera A; Pollock N; Reebye V; Sodergren MH; Dorman S; Littman BH; Doogan D; Huang KW; Habib R; Blakey D; Habib NA; Rossi JJ
    Mol Ther; 2019 May; 27(5):999-1016. PubMed ID: 30852139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis.
    Zhou T; Xie Y; Hou X; Bai W; Li X; Liu Z; Man Q; Sun J; Fu D; Yan J; Zhang Z; Wang Y; Wang H; Jiang W; Gao S; Zhao T; Chang A; Wang X; Sun H; Zhang X; Yang S; Huang C; Hao J; Liu J
    J Exp Clin Cancer Res; 2023 May; 42(1):111. PubMed ID: 37143164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted induction of endogenous NKX3-1 by small activating RNA inhibits prostate tumor growth.
    Ren S; Kang MR; Wang J; Huang V; Place RF; Sun Y; Li LC
    Prostate; 2013 Oct; 73(14):1591-601. PubMed ID: 23836514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.